Vaccines

The agency says additional time is needed to decide upon a phase 4 program.

The vaccine targets an additional 8 unique serotypes that disproportionally affect the adult population.

New report published this week shows the decrease over the last 2 reportable years.

Patients with cancer, cancer survivors, and matched controls maintained immunity against severe COVID-19 for at least 5 months after a third or fourth vaccine dose.

Workplace exposure and living conditions were associated with higher COVID-19 risk, while previous infection, age 65 or older, and Black/African American race were correlated with lower COVID-19 rates.

This study found a substantial increase in Alzheimer's-related deaths during the initial year of the pandemic due to limited access to healthcare, social isolation, and disrupted care routines. However, the second year brought positive developments with prevention strategies and vaccinations, leading to a substantial decline in excess deaths.

Find out why the FDA requested additional data and what this means for dengue prevention.

Though rare, Guillain-Barré syndrome can occur after vaccination. Did Pfizer-BioNTech, Moderna, or Janssen COVID-19 vaccination increase the risk of Guillain-Barré syndrome?

This examination of vaccine introductions worldwide reveals significant gaps in access, especially in low-income countries.

The vaccine candidate, M72/AS01E (M72), could potentially become the first new vaccine to help prevent pulmonary TB, a form of active TB, in more than 100 years.

This rare side effect was witnessed in a small number of people post-vaccine administration.

The findings showed that heterologous vaccination, or mixing different vaccines, was safe and effective, with the Novavax vaccine (NVX-CoV2373) providing enhanced protection against the Omicron variant.

Moderna's RSV vaccine (mRNA-1345) moves closer to regulatory approval with positive data and key submissions to the US FDA, European Medicines Agency, Switzerland's Swissmedic, and Australia's Therapeutic Goods Administration.

From FDA recalls to a new COVID-19 variant, infectious disease news did not slow down in June. Catch up with Contagion's monthly recap of our most-clicked articles.

As of today, the new GSK and Pfizer RSV vaccines are authorized for adults 60 years and older. With CDC Director Dr. Rochelle Walensky’s endorsement, the vaccines are expected to be available as soon as this fall.

There was a lower risk of Omicron infection for each 10-fold increase in preinfection IgG, and for each 2-fold increase in neutralizing antibody titers.

This week's most-read stories included a dive into racial disparities in hepatitis B and increased meningococcal disease in persons with HIV.

The film is part of a GSK campaign, Ask2BSure, that addresses this issue.

The vaccine manufacturer has incorporated spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 for its mRNA-1273.815 COVID-19 vaccine.

Older adults should receive the GSK or Pfizer RSV vaccine this fall, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted yesterday. The recommendation is expected to be finalized by CDC director Dr. Rochelle Walensky.

ABNCoV2, a non-adjuvanted COVID-19 booster vaccine by Bavarian Nordic, demonstrates promising results in phase 2 trials. The vaccine generates strong immune responses, neutralizing multiple variants of concern, including Beta, Delta, and Omicron.

The vaccine induced seroprotective chikungunya virus neutralizing antibodies in 98.9% of participants, regardless of age, and levels were maintained for up to 180 days.

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted 2023-2024 COVID-19 vaccines should be updated to a monovalent XBB strain.

"It does take the immune system a while to build up antibodies and recover," said Madeline King-Patel, PharmD, BCIDP, "So you don't want to give the vaccines too close to each other, or you're not going to get the full benefits."

The FDA's decision to approve Abrysvo was based on data from a Phase 3 clinical trial, which demonstrated the RSV vaccine's efficacy, immunogenicity, and safety in adults aged 60 and older.